GlassScriptPhysician profile
Daniel S Goodman
NPI 1710901640
$2,042.44
in general payments reported to CMS, 2019-2025
22 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $486 · 2021: $407 · 2024: $77.73 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $356.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $418.82 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $313.69 | 2019-2025 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $301.25 | 2019-2021 | |
| Pfizer INC. | $179.44 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $114.62 | 2019-2021 | |
| Lilly USA, LLC | $109.45 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $96.11 | 2019-2021 | |
| Abbvie INC. | $89.80 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.71 | 2019-2021 | |
| Astellas Pharma US INC | $64.67 | 2019 | |
| Amarin Pharma, INC. | $41.14 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $34.62 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.40 | 2025 | |
| Glaxosmithkline, LLC. | $26.81 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $20.93 | 2024 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $18.12 | 2021 | |
| Allergan, INC. | $17.98 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.97 | 2020 | |
| Sanofi-Aventis U.S. LLC | $16.13 | 2019 | |
| Esperion Therapeutics, INC. | $15.39 | 2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $13.00 | 2021 | |
| Sanofi Pasteur INC. | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.